Details of the Drug Combination
General Information of Drug Combination (ID: DCSP1YC)
| Drug Combination Name |
Indazole derivative 5 Arfolitixorin
|
|||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indication |
|
|||||||||||||||||
| Component Drugs | Indazole derivative 5 | Arfolitixorin | ||||||||||||||||
| Small molecular drug | Small molecular drug | |||||||||||||||||
|
|
|||||||||||||||||
| 2D MOL | 2D MOL | |||||||||||||||||
| 3D MOL | 3D MOL | |||||||||||||||||
| High-throughput Screening Result | Testing Cell Line: OVCAR-8 | |||||||||||||||||
| Zero Interaction Potency (ZIP) Score: 7.01 | ||||||||||||||||||
| Bliss Independence Score: 6.34 | ||||||||||||||||||
| Loewe Additivity Score: 4.54 | ||||||||||||||||||
| LHighest Single Agent (HSA) Score: 5.21 | ||||||||||||||||||
Molecular Interaction Atlas of This Drug Combination
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Indazole derivative 5 Interacts with 2 DTT Molecule(s)
|
|||||||||||||||||||||||||||||||
| Indication(s) of Arfolitixorin |
|
||||||||||||||||||||||||||||||
Test Results of This Drug Combination in Other Disease Systems
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References
